Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

M

MiCareo

Status

Unknown

Conditions

CTC and Tumor Related Rare Cell

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03434912
MiC-SRS-HNSCC-001

Details and patient eligibility

About

The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.

Enrollment

80 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  • Over 20 years of age.
  • Cancer patients on immune checkpoint inhibitors.

Exclusion criteria

  • Subjects who have other cancer history
  • Pregnant females
  • Subjects with active, known or suspected autoimmune disease.
  • Known history of human immunodeficiency virus (HIV)

Trial contacts and locations

1

Loading...

Central trial contact

Wang Shin-Hang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems